Multiple System Atrophy (MSA) Market

DelveInsight’s ‘Multiple System Atrophy (MSA) Market Insights, Epidemiology, and Market Forecast–2032’ report deliver an in-depth understanding of the Multiple System Atrophy, historical and forecasted epidemiology as well as the Multiple System Atrophy market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

 

The Multiple System Atrophy market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Multiple System Atrophy market size from 2019 to 2032. The Report also covers current Multiple System Atrophy treatment practice, market drivers, market barriers, SWOT analysis, reimbursement and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

 

Geography Covered

  • The United States
  • The EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019–2032

Multiple System Atrophy Disease Understanding and Treatment Algorithm

Multiple System Atrophy (MSA) is a progressive neurodegenerative disorder characterized by a combination of symptoms that affect both the autonomic nervous system and movement.

 

According to Multiple System Atrophy Coalition, (2021), MSA is broken down into two main subtypes based on the predominant symptom: MSA-predominant Parkinsonism (MSA-P) and MSA-predominant cerebellar ataxia (MSA-C). A patient diagnosed with MSA-P may over time appear to have MSA-C and vice versa, so these categorizations are not always set in stone.

 

MSA-P is more common than MSA-C. The most common symptoms in MSA-P are similar to PD. These symptoms may include difficulty moving, increased falls due to walking problems associated with shuffling of gait, resting tremors, rigidity, slurred speech, voice changes, drooling, difficulty swallowing, and lack of facial expression. The tremor usually disappears when the patient moves and is more prominent at rest, thus the term “resting tremor.” Contrary to this, MSA-C patients present with symptoms that affect the cerebellum, which plays a role in synchronizing motor movement. As a result of the disease, people with MSA-C have difficulty coordinating walking, hand movements, speech, and eye movements.

 

Multiple System Atrophy Diagnosis

The accurate clinical diagnosis of MSA is based on a careful medical history and meticulous neurological examination. Ancillary investigations are helpful to support the diagnosis, rule out potential mimics, and define therapeutic strategies.

 

A detailed clinical evaluation, including medical history, physical, and neurological examinations with special attention to gait, coordination, and muscle tone, is the most important step in evaluating a patient with suspected MSA. The medical history should include questions about the onset and progression of motor symptoms as well as non-motor features, including symptoms of cardiovascular, GI, genitourinary, and motor dysfunction; special attention should be paid to sleep disorders, the presence of cognitive, mood, and behavioral problems, dysphagia, and visual abnormalities. Response to anti-parkinsonian medications, particularly levodopa, is usually sub-optimal and transient. Cold hands and feet are a typical feature of the disease.

Continued in the report…..

 

Multiple System Atrophy Treatment

Multiple System Atrophy is a progressive neurodegenerative disorder characterized by autonomic failure and a variable combination of poor levodopa-responsive Parkinsonism and cerebellar ataxia (CA). Current therapeutic management is based on symptomatic treatment. To date, no curative treatment is available for Multiple System Atrophy.

 

Levodopa remains the first-line therapy with trial up to 2 g total daily dose of levodopa (titrated from 100 mg to 300 mg 3–4 times daily) recommended for at least 3 months. Clinically significant improvement is a 30% decrease in the UMSARS. Levodopa may worsen OH or cause other more severe side effects less common among PD patients.

 

Dopamine agonists may be used as a second choice but lack supporting evidence and are generally not preferred because of their increased side effect profile relative to levodopa. Amantadine, up to 300 mg in three divided doses, is a reasonable alternative treatment option. For the symptomatic treatment of Multiple System Atrophy, Droxidopa was the only therapy approved by the US FDA.

Continued in the report…..

Multiple System Atrophy Epidemiology 

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of Multiple System Atrophy (MSA), Gender-specific Diagnosed Prevalent Cases of Multiple System Atrophy (MSA), Age-specific Diagnosed Prevalent Cases of Multiple System Atrophy (MSA), Type-specific Diagnosed Prevalent Cases of Multiple System Atrophy (MSA)  in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

 

Key Findings

  • In the assessment done by DelveInsight, the estimated total diagnosed prevalent cases of Multiple System Atrophy in the 7MM were 36,117 cases in 2021.
  • The highest total diagnosed prevalent cases of Multiple System Atrophy were accounted by the US in 2021 (15,337 cases), which are expected to show a rise in the future.
  • Among the major European countries, Germany had the highest total diagnosed prevalent cases of Multiple System Atrophy with 2,689 cases, followed by the Italy, which had 2,000 diagnosed prevalent cases in 2021. On the other hand, Spain had the lowest diagnosed prevalent cases (1,507 cases).
  • Japan had 10,934 diagnosed prevalent cases of Multiple System Atrophy for in 2021, accounting for approximately 30% in the 7MM.

Multiple System Atrophy (MSA) Epidemiology

 

Country-Wise Multiple System Atrophy Epidemiology

The epidemiology segment also provides the Multiple System Atrophy epidemiology data and findings across the United States, the EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Multiple System Atrophy Drug Chapters

The drug chapter segment of the Multiple System Atrophy report encloses the detailed analysis of Multiple System Atrophy drugs, mid-phase, and late-stage pipeline drugs. It also helps to understand the Multiple System Atrophy clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details of each included drug and the latest news and press releases.

 

Multiple System Atrophy Emerging Drugs

 

Ampreloxetine (TD-9855): Theravance Biopharma

Ampreloxetine is an investigational, once-daily Norepinephrine Reuptake Inhibitor (NRI) in development for treating patients with symptomatic neurogenic orthostatic hypotension (nOH). It has a high affinity for binding to norepinephrine transporters. By blocking the action of these transporters, ampreloxetine causes an increase in extracellular concentrations of norepinephrine.

Product details in the report…

 

Lu AF82422: H Lundbeck A/S

Lu AF82422 is a human Monoclonal Antibody (mAb) targeting the toxic alpha-synuclein protein known to be a pathological hallmark of multiple spinal atrophy. The compound works similarly to the body’s natural immune system to clear these harmful proteins. As it targets the underlying biology of the disease, Lu AF82422 may potentially slow or stop the progression of MSA, states Lundbeck.

Product detail in the report…

List to be continued in the report…

Multiple System Atrophy (MSA) Market

Multiple System Atrophy Market Outlook

Multiple System Atrophy, a rare disease, is considered to initiate in adulthood (>30 years). Its symptoms are similar to Parkinson’s disease (parkinsonism), cerebellar signs such as progressive impairment of the ability to coordinate voluntary movements (cerebellar ataxia), and impaired functioning of the portion of the nervous system (autonomic nervous system) that regulates certain involuntary body functions (autonomic failure) such as heart rate, blood pressure, sweating, and bowel and bladder control. When parkinsonian symptoms predominate, the disorder is called MSA-P (parkinsonian phenotype); when the cerebellar symptoms predominate, the disorder is called MSA-C (cerebellar phenotype).

 

Considering the approved market segment, NORTHERA (droxidopa) is the first approved therapy for symptomatic nOH. It was first developed by Dainippon Sumitomo Pharma (DSP) and commercialized in Japan in 1989. Chelsea Therapeutics International purchased the drug license from DSP in 2006. In February 2014, Chelsea obtained accelerated approval for NORTHERA for symptomatic benefit in adult patients with nOH from the US FDA and lost exclusivity in February 2021.

Continued in the report…..

 

Key Findings

  • The therapeutic market size of Multiple System Atrophy (MSA) in the 7MM was USD 125 million in 2021.
  • The United States accounts for the highest market size of Multiple System Atrophy (MSA) approximately 68% of the total market size in 7MM in 2021, in comparison to the other major markets i.e., the EU5 countries (the United Kingdom, Germany, Italy, France, and Spain), and Japan.
  • Among the EU5 countries, Germany had the highest market size with USD 5 million in 2021, while Spain had the lowest market size of Multiple System Atrophy with USD 3 million in 2021.
  • The market size for Multiple System Atrophy in Japan was estimated to be USD 21 Million in 2021, which accounts for 17% of the total 7MM market.
  • With the expected launch of upcoming therapy TD-9855, the total market size of Multiple System Atrophy (MSA) is expected to show change in the upcoming years.

 

The United States Market Outlook

This section provides the total Multiple System Atrophy market size and market size by therapies in the United States.

 

EU-5 Market Outlook

The total Multiple System Atrophy market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

 

Japan Market Outlook

The total Multiple System Atrophy market size and market size by therapies in Japan are provided.

Multiple System Atrophy (MSA) Market Share

 

Multiple System Atrophy Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the Multiple System Atrophy or expected to get launched in the market during the study period 2019–2032. The analysis covers Multiple System Atrophy market uptake by drugs; patient uptake by therapies; and sales of each drug. 

 

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

 

Multiple System Atrophy Development Activities

The multiple system atrophy pipeline report provides insights into different therapeutic candidates in phase II, and phase III stages. It also analyzes key players involved in developing targeted therapeutics.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Multiple System Atrophy emerging therapies.

 

Reimbursement Scenario in Multiple System Atrophy

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

 

Competitive Intelligence Analysis

We perform competitive and market Intelligence analysis of the Multiple System Atrophy market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

 

Report Metrics

Details

Study Period

2019 to 2032

Base Year

2021

Forecast Period

2022 to 2032

CAGR

Request Sample to Know

Market Size

USD 125 Million in 2021

Key Companies

H Lundbeck A/S, Theravance Biopharma, Brain Neurotherapy Bio, Inc, Ionis Pharmaceuticals, Inc., Alterity Therapeutics, and others

Scope of the Reports

  • The report covers the descriptive overview of Multiple System Atrophy, explaining its signs and symptoms, causes, classification, and currently available therapies.
  • Comprehensive insight has been provided into the Multiple System Atrophy epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Multiple System Atrophy is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the Multiple System Atrophy market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Multiple System Atrophy market.

 

Report Highlights

  • The robust pipeline with novel MOA and oral ROA and increasing prevalence will positively drive the Multiple System Atrophy market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Multiple System Atrophy R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition and underlying cause.
  • Major players are involved in developing therapies for Multiple System Atrophys. The launch of emerging therapies will significantly impact the Multiple System Atrophy market.
  • Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

 

Multiple System Atrophy Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Multiple System Atrophy Pipeline Analysis
  • Multiple System Atrophy Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

 

Multiple System Atrophy Report Key Strengths

  • 11-Years Forecast
  • 7MM Coverage
  • Multiple System Atrophy Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

 

Multiple System Atrophy Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
  • SWOT analysis

 

Key Questions

Market Insights:

  • What was the Multiple System Atrophy market share (%) distribution in 2019 and how it would look like in 2032?
  • What would be the Multiple System Atrophy total market size as well as market size by therapies across the 7MM during the forecast period (2022–2032)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest Multiple System Atrophy market size during the forecast period (2022–2032)?
  • At what CAGR, the Multiple System Atrophy market is expected to grow at the 7MM level during the forecast period (2022–2032)?
  • What would be the Multiple System Atrophy market outlook across the 7MM during the forecast period (2022–2032)?
  • What would be the Multiple System Atrophy market growth till 2032 and what will be the resultant market size in the year 2032?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

 

Epidemiology Insights:

  • What is the disease risk, burden, and unmet needs of Multiple System Atrophy?
  • What is the historical Multiple System Atrophy patient population in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient population of Multiple System Atrophy at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Multiple System Atrophy?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of Multiple System Atrophy during the forecast period (2022–2032)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2022–2032)?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Multiple System Atrophy along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Multiple System Atrophy in the US, Europe, And Japan?
  • What are the Multiple System Atrophy marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Multiple System Atrophy?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of Multiple System Atrophy?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Multiple System Atrophy therapies?
  • What are the recent therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Multiple System Atrophy and their status?
  • What are the key designations that have been granted for the emerging therapies for Multiple System Atrophy?
  • What are the 7MM historical and forecasted market of Multiple System Atrophy?

 

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Multiple System Atrophy.
  • To understand the future market competition in the Multiple System Atrophy market and an Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Multiple System Atrophy in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the Multiple System Atrophy market.
  • To understand the future market competition in the Multiple System Atrophy market.

1. Key Insights

2. Report Introduction

3. Multiple System Atrophy Market Overview at a Glance

3.1. Market Share (%) Distribution of Multiple System Atrophy by Therapies in 2019

3.2. Market Share (%) Distribution of Multiple System Atrophy by Therapies in 2032

4. Multiple System Atrophy Market: Future Perspective

5. Executive Summary of Multiple System Atrophy (MSA)

6. Key Events

7. Disease Background and Overview: Multiple System Atrophy (MSA)

7.1. Introduction

7.2. Subtypes of MSA

7.2.1. MSA-P

7.2.2. MSA-C

7.3. Etiology of MSA

7.4. Signs and symptoms of MSA

7.5. The neuropathology of MSA

7.6. Pathogenesis of MSA

7.7. Biomarkers

7.8. Diagnosis of MSA

7.9. Diagnostic guidelines for MSA

7.10. Diagnostic algorithm for MSA

7.11. Treatment for Multiple System Atrophy

8. Epidemiology and Patient Population

8.1. Key Findings

8.2. Methodology of Epidemiology

8.3. Assumptions and Rationale: 7MM

8.3.1. United States

8.3.2. EU5 Countries

8.3.3. Japan

8.4. Total Diagnosed Prevalent Cases of Multiple System Atrophy in the 7MM

8.5. The United States

8.5.1. Diagnosed Prevalent Cases of MSA in the United States

8.5.2. Gender-specific Diagnosed Prevalent Cases of MSA in the United States

8.5.3. Age-specific Diagnosed Prevalent Cases of MSA in the United States

8.5.4. Type-specific Diagnosed Prevalent Cases of MSA in the United States

8.6. Major Five European Countries

8.6.1. Germany

8.6.1.1. Total Diagnosed Prevalent Cases of MSA

8.6.1.2. Gender-specific Diagnosed Prevalent Cases of MSA

8.6.1.3. Age-specific Diagnosed Prevalent Cases of MSA

8.6.1.4. Type-specific Diagnosed Prevalent Cases of MSA

8.6.2. France

8.6.2.1. Total Diagnosed Prevalent Cases of MSA

8.6.2.2. Gender-specific Diagnosed Prevalent Cases of MSA

8.6.2.3. Age-specific Diagnosed Prevalent Cases of MSA

8.6.2.4. Type-specific Diagnosed Prevalent Cases of MSA

8.6.3. Italy

8.6.3.1. Total Diagnosed Prevalent Cases of MSA

8.6.3.2. Gender-specific Diagnosed Prevalent Cases of MSA

8.6.3.3. Age-specific Diagnosed Prevalent Cases of MSA

8.6.3.4. Type-specific Diagnosed Prevalent Cases of MSA

8.6.4. Spain

8.6.4.1. Total Diagnosed Prevalent Cases of MSA

8.6.4.2. Gender-specific Diagnosed Prevalent Cases of MSA

8.6.4.3. Age-specific Diagnosed Prevalent Cases of MSA

8.6.4.4. Type-specific Diagnosed Prevalent Cases of MSA

8.6.5. The United Kingdom

8.6.5.1. Total Diagnosed Prevalent Cases of MSA

8.6.5.2. Gender-specific Diagnosed Prevalent Cases of MSA

8.6.5.3. Age-specific Diagnosed Prevalent Cases of MSA

8.6.5.4. Type-specific Diagnosed Prevalent Cases of MSA

8.7. Japan

8.7.1. Diagnosed Prevalent Cases of MSA in Japan

8.7.2. Gender-specific Diagnosed Prevalent Cases of MSA in Japan

8.7.3. Age-specific Diagnosed Prevalent Cases of MSA in Japan

8.7.4. Type-specific Diagnosed Prevalent Cases of MSA in Japan

9. Patient Journey

10. Emerging Drugs

10.1. Key Competitors

10.2. Lu AF82422: H Lundbeck A/S

10.2.1. Product description

10.2.2. Other development activities

10.2.3. Clinical development

10.2.4. Clinical trial information

10.2.5. Safety and efficacy

10.2.6. Product profile

10.2.7. Analyst’s views

10.3. Ampreloxetine (TD-9855): Theravance Biopharma

10.3.1. Product description

10.3.2. Other developmental activities

10.3.3. Clinical development

10.3.4. Clinical trial information

10.3.5. Safety and efficacy

10.3.6. Product profile

10.3.7. Analyst’s views

10.4. AAV2-GDNF Gene Therapy: Brain Neurotherapy Bio, Inc.

10.4.1. Product description

10.4.2. Other development activities

10.4.3. Clinical development

10.4.4. Clinical trial information

10.4.5. Product profile

10.4.6. Analyst’s views

10.5. ION464: Ionis Pharmaceuticals, Inc.

10.5.1. Product description

10.5.2. Other development activities

10.5.3. Clinical development

10.5.4. Clinical trial information

10.5.5. Product profile

10.5.6. Analyst’s views

10.6. ATH434: Alterity Therapeutics

10.6.1. Product description

10.6.2. Other development activities

10.6.3. Clinical development

10.6.4. Clinical trial information

10.6.5. Product profile

10.6.6. Analyst’s views

11. Multiple System Atrophy (MSA): Seven Major Market Analysis

11.1. Key Findings

11.2. Methodology of MSA Market

11.3. Market Outlook

11.4. Potential of Emerging Therapies

11.5. Key Market Forecast Assumptions

11.6. Market Size of MSA in the 7MM

11.7. Market Size of MSA by Therapies in the 7MM

11.8. Market Size of Multiple System Atrophy in the United States

11.8.1. Total Market Size of MSA

11.8.2. Market Size of Multiple System Atrophy by Therapies

11.9. Market Size of Multiple System Atrophy in the EU5

11.9.1. Germany

11.9.1.1. Total Market Size of Multiple System Atrophy

11.9.1.2. Market Size of Multiple System Atrophy by Therapies

11.9.2. France

11.9.2.1. Total Market Size of Multiple System Atrophy

11.9.2.2. Market Size of Multiple System Atrophy by Therapies

11.9.3. Italy

11.9.3.1. Total Market Size of Multiple System Atrophy

11.9.3.2. Market Size of Multiple System Atrophy by Therapies

11.9.4. Spain

11.9.4.1. Total Market Size of Multiple System Atrophy

11.9.4.2. Market Size of Multiple System Atrophy by Therapies

11.9.5. The United Kingdom

11.9.5.1. Total Market Size of Multiple System Atrophy

11.9.5.2. Market Size of Multiple System Atrophy by Therapies

11.10. Market Size of Multiple System Atrophy in Japan

11.10.1. Total Market Size of Multiple System Atrophy

11.10.2. Market Size of Multiple System Atrophy by Therapies

12. Key Opinion Leaders’ View

13. Market Drivers

14. Market Barriers

15. SWOT Analysis

16. Unmet Needs

17. Reimbursement and Market Access

18. Appendix

18.1. Bibliography

18.2. Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

List of Table

Table 1: Summary of Multiple System Atrophy Market and Epidemiology (2019–2032)

Table 2: Key Events

Table 3: Current Consensus Criteria for the Diagnosis of MSA

Table 4: Criteria for Possible MSA

Table 5: Additional Features of Possible MSA

Table 6: Criteria for the Diagnosis of Probable MSA

Table 7: Features supporting (red flags) and not supporting a diagnosis of MSA

Table 8: Total Diagnosed Prevalent cases of Multiple System Atrophy in the 7MM (2019–2032)

Table 9: Diagnosed Prevalent Cases of Multiple System Atrophy in the US (2019–2032)

Table 10: Gender-specific Diagnosed Prevalent Cases of Multiple System Atrophy in the US (2019–2032)

Table 11: Age-specific Diagnosed Prevalent Cases of Multiple System Atrophy in the US (2019–2032)

Table 12: Type-specific Diagnosed Prevalent Cases of Multiple System Atrophy in the US (2019–2032)

Table 13: Total Diagnosed Prevalent Cases of Multiple System Atrophy in the EU5 (2019–2032)

Table 14: Gender-specific Diagnosed Prevalent Cases of Multiple System Atrophy in Germany (2019–2032)

Table 15: Gender-specific Diagnosed Prevalent Cases of Multiple System Atrophy in France (2019–2032)

Table 16: Gender-specific Diagnosed Prevalent Cases of Multiple System Atrophy in Italy (2019–2032)

Table 17: Gender-specific Diagnosed Prevalent Cases of Multiple System Atrophy in Spain (2019–2032)

Table 18: Gender-specific Diagnosed Prevalent Cases of Multiple System Atrophy in the UK (2019–2032)

Table 19: Gender-specific Diagnosed Prevalent Cases of Multiple System Atrophy in the EU5 (2019–2032)

Table 20: Age-specific Diagnosed Prevalent Cases of Multiple System Atrophy in Germany (2019–2032)

Table 21: Age-specific Diagnosed Prevalent Cases of Multiple System Atrophy in France (2019–2032)

Table 22: Age-specific Diagnosed Prevalent Cases of Multiple System Atrophy in Italy (2019–2032)

Table 23: Age-specific Diagnosed Prevalent Cases of Multiple System Atrophy in Spain (2019–2032)

Table 24: Age-specific Diagnosed Prevalent Cases of Multiple System Atrophy in the UK (2019–2032)

Table 25: Type-specific Diagnosed Prevalent Cases of Multiple System Atrophy in Germany (2019–2032)

Table 26: Type-specific Diagnosed Prevalent Cases of Multiple System Atrophy in France (2019–2032)

Table 27: Type-specific Diagnosed Prevalent Cases of Multiple System Atrophy in Italy (2019–2032)

Table 28: Type-specific Diagnosed Prevalent Cases of Multiple System Atrophy in Spain (2019–2032)

Table 29: Type-specific Diagnosed Prevalent Cases of Multiple System Atrophy in the UK (2019–2032)

Table 30: Type-specific Diagnosed Prevalent Cases of Multiple System Atrophy in the EU5 (2019–2032)

Table 31: Diagnosed Prevalent Cases of Multiple System Atrophy in Japan (2019–2032)

Table 32: Gender-specific Diagnosed Prevalent Cases of Multiple System Atrophy in Japan (2019–2032)

Table 33: Age-specific Diagnosed Prevalent Cases of Multiple System Atrophy in Japan (2019–2032)

Table 34: Type-specific Diagnosed Prevalent Cases of Multiple System Atrophy in Japan (2019–2032)

Table 35: Comparison of Emerging Drugs for Multiple System Atrophy

Table 36: Lu AF82422, Clinical Trial Description, 2022

Table 37: Ampreloxetine (TD-9855), Clinical Trial Description, 2022

Table 38: AAV2-GDNF gene therapy, Clinical Trial Description, 2022

Table 39: ION464, Clinical Trial Description, 2022

Table 40: ATH434, Clinical Trial Description, 2022

Table 41: Key Market Forecast Assumptions for Ampreloxetine (TD-9855)

Table 42: Market Size of Multiple System Atrophy in the 7MM in USD Million (2019–2032)

Table 43: Market Size of Multiple System Atrophy by Therapies in the 7MM in USD Million (2019–2032)

Table 44: The United States Market Size of Multiple System Atrophy in USD Million (2019–2032)

Table 45: Market Size of Multiple System Atrophy by Therapies in the US in USD Million (2019–2032)

Table 46: The EU5 Market Size of Multiple System Atrophy in USD Million (2019–2032)

Table 47: Market Size of Multiple System Atrophy by Therapies in Germany in USD Million (2019–2032)

Table 48: Market Size of Multiple System Atrophy by Therapies in France in USD Million (2019–2032)

Table 49: Market Size of Multiple System Atrophy by Therapies in Italy in USD Million (2019–2032)

Table 50: Market Size of Multiple System Atrophy by Therapies in Spain in USD Million (2019–2032)

Table 51: Market Size of Multiple System Atrophy by Therapies in the United Kingdom in USD Million (2019–2032)

Table 52: Market Size of Multiple System Atrophy by Therapies in the EU5 in USD Million (2019–2032)

Table 53: Market Size of Multiple System Atrophy in Japan, in USD Million (2019–2032)

Table 54: Market Size of Multiple System Atrophy by Therapies in Japan in USD Million (2019–2032)

List of Figures

Figure 1: Neurological entities describing MSA

Figure 2: Sub-Types of Multiple System Atrophy

Figure 3: Clinical Presentations in MSA Patients

Figure 4: Neuropathology of MSA and cell-to-cell propagation of α-syn

Figure 5: Alpha-synuclein in the pathogenesis of MSA

Figure 6: Mitochondria in the pathogenesis of MSA

Figure 7: Available Models of MSA

Figure 8: Current and future diagnostic biomarkers of MSA

Figure 9: Diagnostic scheme for MSA according to the current consensus diagnostic criteria

Figure 10: Treatment and Management of Multiple System Atrophy

Figure 11: Total Diagnosed Prevalent Cases of Multiple System Atrophy in the 7MM (2019–2032)

Figure 12: Diagnosed Prevalent Cases of Multiple System Atrophy in the US (2019–2032)

Figure 13: Gender-specific Diagnosed Prevalent Cases of Multiple System Atrophy in the US (2019–2032)

Figure 14: Age-specific Diagnosed Prevalent Cases of Multiple System Atrophy in the US (2019–2032)

Figure 15: Type-specific Diagnosed Prevalent Cases of Multiple System Atrophy in the US (2019–2032)

Figure 16: Total Diagnosed Prevalent Cases of Multiple System Atrophy in the EU5 (2019–2032)

Figure 17: Gender-specific Diagnosed Prevalent Cases of Multiple System Atrophy in the EU5 (2019–2032)

Figure 18: Age-specific Diagnosed Prevalent Cases of Multiple System Atrophy in the EU5 (2019–2032)

Figure 19: Type-specific Diagnosed Prevalent Cases of Multiple System Atrophy in the EU5 (2019–2032)

Figure 20: Diagnosed Prevalent Cases of Multiple System Atrophy in Japan (2019–2032)

Figure 21: Gender-specific Diagnosed Prevalent Cases of Multiple System Atrophy in Japan (2019–2032)

Figure 22: Age-specific Diagnosed Prevalent Cases of Multiple System Atrophy in Japan (2019–2032)

Figure 23: Type-specific Diagnosed Prevalent Cases of Multiple System Atrophy in Japan (2019–2032)

Figure 24: Patient Journey

Figure 25: Possible Potential of Emerging Therapies

Figure 26: Market Size of Multiple System Atrophy in the 7MM, in USD Million (2019–2032)

Figure 27: Market Size of Multiple System Atrophy by Therapies in the 7MM in USD Million (2019–2032)

Figure 28: Market Size of Multiple System Atrophy in the United States, USD Million (2019–2032)

Figure 29: Market Size of Multiple System Atrophy by Therapies in the United States, in USD Million (2019–2032)

Figure 30: Market Size of Multiple System Atrophy in the EU5, USD Million (2019–2032)

Figure 31: Market Size of Multiple System Atrophy by Therapies, in the EU5, in USD Million (2019–2032)

Figure 32: Market Size of Multiple System Atrophy in Japan, USD Million (2019–2032)

Figure 33: Market Size of Multiple System Atrophy by Therapies in Japan, in USD Million (2019–2032)

Figure 34: Market Drivers

Figure 35: Market Barriers

Figure 36: SWOT Analysis

Figure 37: Unmet Needs

Figure 38: European pharmaceutical Markets

H Lundbeck A/S
Theravance Biopharma
Brain Neurotherapy Bio, Inc
Ionis Pharmaceuticals, Inc.
Alterity Therapeutics

 

Forward to Friend

Need A Quote